Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
GGH	8836	PEMETREXED DISODIUM	CHEMBL1200373		PharmGKB
GGH	8836	BEVACIZUMAB	CHEMBL1201583		PharmGKB
GGH	8836	THIOGUANINE	CHEMBL727		NCI	16041371

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
GGH	rs11545078	A	methotrexate	efficacy	no		Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid.	22450926	827863309
GGH	rs3758149	AA + AG	methotrexate	efficacy	yes		Genotypes AA + AG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.	19827168	769170797
GGH	rs11545078	GG	methotrexate	"efficacy","toxicity"	no	This SNP was presented as GGH 452 C>T. No subjects were found that were homozygous for the variant allele. No association was found between this SNP and response to or toxicity due to treatment with methotrexate.	Genotype GG is not associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AG.	22763757	1183690829
GGH	rs17279558	C	methylphenidate	efficacy	no	The authors carried out a GWAS in a Spanish cohort of pediatric patients, than performed a meta-analysis using data from the Spanish cohort and data from a Brazilian adult patient cohort. This variant was not significant in the meta-analysis after Bonferroni correction had been applied, and was nominally significant (i.e did not reach genome-wide significance) in the initial GWAS in the Spanish cohort. Response was measured on the Clinical Global Impression-Improvement scale (CGI-I). A CGI-I score of two points or less after eight weeks of treatment was considered a good response.	Allele C is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.	29382897	1449166337